

---

**CORRIGENDUM**

## Radioimmunotherapy of human tumours

Steven M. Larson, Jorge A. Carrasquillo, Nai-Kong V. Cheung & Oliver W. Press

*Nature Reviews Cancer* **15**, 347–360 (2015)

Nai-Kong V. Cheung and Steven M. Larson have now declared competing interests that were not stated in the version of this article that was originally published. The following competing interests statement has now been added to the online version: "S.M.L. has ownership interest (including patents) in nanoparticle constructs of C-DOTs, use of mAb A33, and small molecular radio label drugs in Dasatinib and the HSP 90 inhibitor PUH71 and kinetics of immunoPET localization to tumours. N.-K.V.C. has ownership interest (including patents) in scfv constructs of anti-GD2 antibodies, therapy-enhancing glucan, use of mAb 8H9, methods for preparing and using scFv, GD2 peptide mimics, methods for detecting MRD, anti-GD2 antibodies, generation and use of HLA-A2-restricted peptide-specific mAbs and CARs, high-affinity anti-GD2 antibodies, multimerization technologies, bispecific HER2 and CD3 binding molecules, affinity matured hu8H9, anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof, and ROR2 antibodies. J.A.C. and O.W.P. declare no competing interests."